High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD

Angioimmunoblastic lymphadenopathy with dysproteinemia (or dysgammaglobulinemia) (AILD) is a lymphoproliferative disorder with cytogenetic and molecular abnormalities characteristic of malignant T-cell lymphoma (angioimmunoblastic T-cell lymphoma — AITL). We report the clinical course of a 58-year-o...

Full description

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 25; no. 3; pp. 267 - 270
Main Authors Lindahl, Jenny, Kimby, Eva, Björkstrand, Bo, Christensson, Birger, Hellström-Lindberg, Eva
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 01.03.2001
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Angioimmunoblastic lymphadenopathy with dysproteinemia (or dysgammaglobulinemia) (AILD) is a lymphoproliferative disorder with cytogenetic and molecular abnormalities characteristic of malignant T-cell lymphoma (angioimmunoblastic T-cell lymphoma — AITL). We report the clinical course of a 58-year-old male patient with unusually aggressive AILD, including severe hemolysis and Guillain–Barré syndrome, who entered complete remission after CHOP therapy, but had a full relapse after 2 months. At relapse, treatment with high-dose chemotherapy followed by autologous peripheral stem cell transplantation (APSCT) with CD34 selected cells was shown to be successful. The patient is alive and disease-free 3 years after diagnosis and 32 months after APSCT. Considering the poor prognosis of the majority of patients with AILD, intensive treatment followed by APSCT, may be a subject for further studies.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0145-2126
1873-5835
DOI:10.1016/S0145-2126(00)00134-X